Cameron, D A <br/><br/>
Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.  [electronic resource] 

 -  British journal of cancer  Dec 2008 
 - 1984-90 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6604790  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Estradiol--adverse effects<br/>Fulvestrant<br/>Hormone Replacement Therapy<br/>Humans<br/>Neoplasm Staging<br/>Receptors, Estrogen--metabolism<br/>Substrate Specificity